Pfizer partners with USA's NABP to warn about counterfeit Rx drugs
Global drugs behemoth Pfizer (NYSE: PFE) and the USA’s National Association of Boards of Pharmacy (NABP) are launching a new effort to draw attention to the risks associated with counterfeit prescription medicines and help patients learn how to safely buy medicines online.
Prescription medicines are among the most counterfeited consumer goods. Worldwide sales of counterfeit medicines were estimated to exceed $75 billion last year – an increase of 90% since 2005. Last year, one in six Americans purchased medicines on the Internet, potentially exposing them to harmful counterfeits, noted a joint press statement.
The Pfizer/NABP campaign includes a web site called http://www.AWARERx.com, a video series on a new YouTube channel called http://www.youtube.com/spotfakemeds, and takeovers of web sites counterfeiters have previously used to sell counterfeit copies of Pfizer drugs.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze